The Business Group on Health survey found that among companies that cover GLP-1s for weight management, 10% are unlikely or very unlikely to continue the coverage in 2027 for cost reasons, according to Magda Rusinowski, vice president of the non-profit, which represents employers' perspectives on health-related issues
F., Wettergren, A., Pedersen, J
Besides curbing appetite, Semaglutide GLP-1 also decelerates gastric emptying, contributing to a prolonged sensation of fullness after eating
Its commonly used on the face, neck, and chest
Youre not getting a plug-and-play system, but real clinical oversight